In a deal worth up to $760 million, AstraZeneca Plc announced on Tuesday that it had reached an agreement with Swiss biotechnology firm Neurimmune to develop an antibody-based therapy for a rare, underdiagnosed condition that can lead to heart failure. Alexion and Neurimmune from AstraZeneca’s rare diseases unit will collaborate to evaluate NI006, a monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy.